Market Access, HEOR and RWE M&A: The Evidence to Access Shift

Why market access, HEOR and RWE businesses are attracting strategic and private equity buyers, and the capabilities those buyers value.

Market access has often been most visible around the later stages of product development and launch, through health technology assessment, pricing, reimbursement and payer engagement. That is now too narrow a way to understand the discipline.

Decisions taken years before launch, including clinical endpoints, trial comparators, patient population definitions and evidence generation plans, materially influence whether a product secures a positive HTA recommendation, achieves reimbursement at an acceptable price and is adopted at scale. Market access considerations have therefore become more influential earlier in development and more continuous across the product lifecycle.

This is changing what pharmaceutical, biotechnology and medtech companies require from their advisers, bringing health economics and outcomes research (HEOR) and real-world evidence (RWE) closer to the centre of the market access proposition. It is also driving a sustained period of investment and consolidation as buyers assemble broader evidence and access capabilities.

Market access is becoming more influential earlier

The underlying purpose of market access is unchanged. Companies need to demonstrate sufficient clinical, economic and wider value for their products to be funded and adopted.

What is changing is the extent to which those considerations shape earlier development decisions. Trial design, endpoint selection, comparator choice and long-term evidence planning all affect how a product is subsequently assessed by HTA bodies and payers. Identifying evidence gaps late in development creates a risk that they have already become difficult, expensive or impossible to close.

HEOR and RWE are therefore increasingly part of a connected approach to value demonstration, rather than being commissioned as isolated technical workstreams. Economic modelling helps identify future evidence requirements. Real-world data addresses uncertainties that conventional trials will not resolve. Early payer research shapes positioning, evidence plans and development decisions.

The resulting work spans HTA submissions, pricing, payer engagement, launch, post-market outcomes studies and future reassessment. These activities frequently overlap or run in parallel rather than following a neat sequence, which is why clients increasingly value advisers able to connect them.

For pharmaceutical companies, the commercial consequences of getting this wrong have increased. Decisions made during development can restrict pricing flexibility, delay reimbursement or weaken adoption, and those outcomes are expensive to correct.

Why this is happening now

Four developments are accelerating this change.

EU HTA reform. The EU Health Technology Assessment Regulation introduced Joint Clinical Assessments for new oncology medicines and advanced therapy medicinal products from January 2025, with the scope widening in stages thereafter. The regime creates a more coordinated approach to clinical assessment across Europe, while pricing and reimbursement decisions remain largely national. Companies therefore need evidence strategies capable of supporting a shared European assessment while still accounting for different national systems, methodologies and payer requirements. This increases the value of providers that can combine international evidence planning with detailed local reimbursement expertise.

The growing use of real-world evidence. Real-world data now informs economic models, provides evidence on treatment pathways, helps assess whether trial findings apply to routine clinical populations, and addresses uncertainty over longer-term outcomes. NICE's own reporting found that more than 95% of evidence reviews in its clinical guidelines used real-world data in their cost-effectiveness modelling. A separate review found that 96% of cancer single technology appraisals used real-world data in their cost-effectiveness modelling. Those figures indicate that RWE has moved from a supplementary capability to a central part of many evidence and access strategies.

More complex therapies. Rare disease, oncology, cell and gene therapies and other specialist products typically involve smaller patient populations, limited comparative evidence and material uncertainty over long-term outcomes. They also carry substantial financial consequences for payers. Products of this type require more sophisticated evidence synthesis, economic modelling, pricing strategy and post-launch evidence planning, and their growing share of industry pipelines raises demand for advisers who can work credibly across all of those areas.

Sustained payer scrutiny. Healthcare systems remain under pressure to control expenditure while providing access to innovation. Greater scrutiny of pharmaceutical spending does not reduce demand for market access support. It raises the standard of evidence required to justify pricing, reimbursement and adoption.

What recent transactions show

Buyers are not generally acquiring these businesses simply to add revenue or headcount. They are buying specialist capabilities that would take time and money to build internally.

Prescient Healthcare Group, backed by Bridgepoint, acquired Uptake in January 2026 to add commercial and launch expertise, followed by Dolon in March 2026 for strategic pricing and market access capability across the drug lifecycle, with particular strength in rare disease and oncology. Two acquisitions in three months, each addressing a different capability gap, illustrate the pattern clearly.

Red Nucleus acquired Bridge Medical Consulting in February 2026, strengthening its HEOR, evidence synthesis, modelling and statistics capabilities. Eclipse advised the shareholders of Bridge Medical Consulting on the transaction. It allowed a broad pharma services platform to add specialist evidence expertise alongside its existing market access, medical affairs and commercialisation offering.

Newmarket Strategy, backed by Baird Capital, acquired Visible Analytics in April 2026, adding HEOR, modelling, evidence synthesis and data analytics to an established market access and health policy business. The stated rationale was to complete a full-service market access proposition rather than simply to increase scale.

Other transactions show the same approach. Petauri combined Mtech Access and Delta Hat in June 2024, pairing global market access with technical health-economic modelling. Helios Global Group, a healthcare communications business, acquired HEOR and market access specialist Cogentia in February 2024. Herspiegel added FIECON in April 2025 for health economics, HTA and pricing, then Decisive Consulting in June 2025 for global access strategy, subsequently bringing the businesses together under the Acumetis brand.

Private equity has also been willing to back specialists directly. Queen's Park Equity's investment in Initiate Consultancy in December 2025 reflects appetite for a specialist market access and HEOR business with recognised technical authority across HTA, economic modelling, evidence synthesis, payer research and value communication, together with the potential to build a wider platform around that base. CBPE's investment in Access Infinity in February 2026 is a different proposition again. Access Infinity combines market access consulting with proprietary technology supporting pricing and evidence strategy, and the investment was made to support both product development and international expansion.

Geography is also important. While European clinical assessment is becoming more coordinated, pricing and reimbursement remain national, and local payer knowledge is difficult to replicate.

Kintiga, formerly MAP Patient Access, has pursued this strategy through the acquisitions of AxTalis in Benelux and SKC in Germany. This demonstrates that building an international platform does not necessarily mean centralising delivery or removing local expertise.

The common feature across these transactions is ownership of expertise, relationships, methodologies or technology that a buyer would find difficult to build quickly or recruit cheaply.

Platforms and specialists can both succeed

Consolidation does not mean that every successful business in this market will end up inside a global integrated platform.

Larger platforms offer real advantages. They can provide greater delivery capacity, broader geographic coverage and the ability to support clients across more of the product lifecycle. They are often better placed to invest in technology, quality systems, recruitment and international business development.

Specialist consultancies retain advantages of their own. Market access depends on scientific credibility, therapeutic expertise, senior judgement and local payer knowledge. Those attributes are difficult to standardise and can be weakened by poor integration. A highly regarded boutique in economic modelling, evidence synthesis, oncology, rare disease or a particular reimbursement market remains attractive to clients and buyers alike.

There is, however, an important qualification to the integrated platform argument. Acquirers consistently describe integrated platforms as the model clients want, and the commercial logic is credible. The public evidence for that preference comes largely from acquirers themselves. There is relatively little published evidence that pharmaceutical procurement teams are consolidating supplier relationships at the pace those descriptions imply, and several recent transactions have explicitly preserved the acquired firm's specialist focus.

The market therefore looks likely to support two successful models. The first is a scaled platform with genuinely connected capabilities across the evidence and access value chain. The second is a highly differentiated specialist with recognised authority in an area that clients consider difficult to replicate. The weaker position is the undifferentiated generalist, offering neither the breadth of a platform nor the authority of a specialist.

Technology is an enabler rather than the thesis

Technology and AI are becoming more important within market access, HEOR and RWE. The most credible current applications include literature screening, evidence extraction, economic model development, analogue analysis, payer intelligence and the management of evidence across multiple markets. Used well, these tools help scarce specialists work faster and more consistently, and can support better margins by reducing manual effort in evidence generation and document production.

The constraints are equally real. Economic models, HTA submissions and payer strategies must remain transparent, reproducible and capable of withstanding detailed scrutiny by HTA bodies and payers. Scientific leadership, local interpretation and professional accountability cannot be automated.

For owners and investors, one distinction is particularly important. A consultancy whose employees use standard AI tools is not a software business. Technology may improve productivity without creating proprietary value or recurring revenue. A genuine technology-enabled proposition requires differentiated functionality or data, meaningful client adoption, and evidence that the product is embedded in customer workflows. It should also be clear whether clients pay separately for the technology or whether it is an internal delivery tool. Both models can be valuable, although they should not be presented or valued as though they were the same.

What buyers are looking for

Scarce technical expertise. Defensible capability across HEOR, economic modelling, evidence synthesis, RWE and local reimbursement is attracting the strongest interest, alongside therapeutic depth in complex areas such as oncology, rare disease and advanced therapies. The harder a capability is to recruit or replicate, the greater its strategic value.

A defensible market position. Buyers need to understand why clients choose a business and why they will continue to do so. For a platform, that may be genuinely connected delivery across evidence, access and launch. For a specialist, it may be recognised technical authority, senior involvement or a strong reputation in a particular market. Breadth without differentiation is unlikely to be sufficient.

High-quality revenue. Longstanding relationships and repeat assignments are valuable, particularly where they demonstrate trust and provide visibility over future work. Repeat project revenue is valuable, but it is not the same as contractually recurring revenue, and owners should be able to explain and evidence the distinction. Buyers will also examine client concentration, the balance between large and smaller accounts, pricing power, and whether relationships sit with the organisation or with an individual founder.

Management depth. A business dependent entirely on its founders is harder to acquire and harder to scale. Buyers look for a capable second tier with genuine responsibility for client relationships, delivery, recruitment, quality and business development. In a people-led market, a demonstrated ability to retain and develop scarce technical talent matters considerably.

Proof of integration. Businesses pursuing a platform strategy need to show more than a collection of capabilities. Buyers will look for evidence that teams share clients, collaborate on proposals, coordinate delivery and generate real cross-selling. They will also want to see that growth has not diluted technical quality, senior attention or the culture that made the constituent businesses attractive.

The strategic choice for owners

Market access can no longer be understood primarily through its most visible late-stage activities in HTA, pricing, reimbursement and launch. It has become more influential earlier in development and more closely connected to evidence generation throughout the product lifecycle. HEOR and RWE increasingly sit at the centre of that change, providing much of the evidence through which clinical innovation is translated into economic value and, ultimately, patient access.

This explains why strategic buyers and private equity investors are building across the sector. They are acquiring scarce capabilities that strengthen wider evidence and access propositions. The strongest platforms will combine breadth with genuine technical depth. The strongest specialists will remain differentiated in areas that cannot easily be industrialised. Technology will improve how both models operate without replacing expertise, credibility or judgement.

For owners, this creates a clearer strategic choice than the market has previously required. Operating in a growing sector will not by itself command a premium. Buyers are likely to place the greatest value on businesses that have made a deliberate strategic choice, either to build a genuinely integrated platform or to establish a highly differentiated specialist position around capabilities that are difficult to replicate. In either case, owners will need to demonstrate that the strategy is working in practice.

Eclipse Corporate Finance is a healthcare-focused M&A advisory firm. We advised the shareholders of Bridge Medical Consulting on its sale to Red Nucleus. We would be pleased to speak in confidence with owners considering how these market developments may affect the strategic options for their business. Further details of how we support pharma services businesses can be found here: Pharma Services M&A Advisors.